Sublingual Cannabidiol for Chronic Pain

• Status: Not yet recruiting
• Trial end date: 2023-07-31
• Target enrollment: 0
• Participant gender: All

Summary

This study involves taking a high-cannabidiol (CBD) sublingual product for 6 weeks in order to assess the impact of CBD on chronic pain, conventional medication use, clinical state, quality of life, cognition, and where applicable, brain structure and function via neuroimaging.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Staci Gruber, Ph.D.
• Treatments: Cannabidiol; Epidiolex

Criteria

Inclusion Criteria:

• Subject has provided informed consent

• Subject is 21 or older

• Subject is a native English speaker or acquired English prior to age 5

• Subject endorses a chronic pain condition including, but not limited to, chronic pain due to injury, musculoskeletal pain, arthritis (including osteoarthritis and rheumatoid arthritis), fibromyalgia, bursitis, endometriosis, etc.

Exclusion Criteria:

• Non-native English speakers

• Estimated IQ < 75

• A history of head injury or loss of consciousness greater than 5 minutes

• Currently uses marijuana or CBD products

• Female subjects will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding

• Presence of a serious medical illness, including liver, kidney, or cardiovascular disease (hyper/hypotension, cardiac disorders), or neurological disorder (including seizure disorder)

• Neuropathic pain or cancer-related pain

• Disclosure of a genetic polymorphism affecting CYP2C9 function

• Coconut allergy, as the product is formulated in coconut oil